Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer
NCT05319314Phase 2Recruiting
- Sponsor
- Lyell Immunopharma
- Start
- Aug 2022
- Primary completion
- Jun 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GCC19CAR-T in colorectal cancer (CRC), sponsored by Lyell Immunopharma. Primary endpoints: Dose-Limiting Toxicities at 28 days, Maximum Tolerable Dose at 28 days and 2 more. Started Aug 2022; status: recruiting.
02
Drugs
GCC19CAR-T
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05319314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05319314.